Key facts
- BlossomHill Therapeutics’s last known valuation is $413.1M (Dec 2025).
- It has raised $257.1M across 4 recorded rounds; the latest was Later Stage VC ($84.2M) in Nov 2025.
- Notable investors include OrbiMed, Cormorant Asset Management, Vivo Capital, BioTrack Capital, Brahma Capital (Texas) — 10 tracked in total.
- BlossomHill Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Dec 2025 ($84.2M sold to 47 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for BlossomHill Therapeutics
Funding rounds
4 roundsAbout BlossomHill Therapeutics
Operator of a biopharmaceutical company designed to develop treatments for oncology and autoimmune diseases. The company offers innovative drug design expertise and precision medicine approaches, enabling patients with challenging medical conditions to access therapies addressing resistance mechanisms in current treatments.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 55
- Website
- bhtherapeutics.com/
- Ownership
- Privately Held (backing)
BlossomHill Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BlossomHill Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BlossomHill Therapeutics in its N-PORT filings yet. We sweep new filings monthly.